Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Foghorn Therapeutics Inc. (FHTX) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / October 13, 2026 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Foghorn Therapeutics Inc. ("Foghorn" or "the Company") (NASDAQ:FHTX). Investors who purchased Foghorn securities are encouraged to obtain additional information and assist the investigation by visiting the firm 's site: bgandg.com/cases/foghorn-therapeutics-inc-fhtx-class_action_lawsuit.
Foghorn Investigation Details
On October 1, 2026, Foghorn Therapeutics Inc. announced that, following a review of clinical data from the Phase 1 dose-escalation trial of FHD-909 (LY4050784), the Company and its collaboration partner, Eli Lilly, decided not to advance the program into the clinical development expansion phase. The companies also decided to discontinue development of their Selective SMARCA2 degrader program and indicated that they did not anticipate further collaboration activities. As a result, Foghorn stated that it would prioritize resources toward its proprietary portfolio programs. Following this news, Foghorn 's stock price declined more than 30.8% on October 2, 2026.
What 's Next for Foghorn Investors?
If you are aware of any facts relating to this investigation or purchased Foghorn securities, you can assist this investigation by visiting the firm 's site: bgandg.com/cases/foghorn-therapeutics-inc-fhtx-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Foghorn Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys ' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Foghorn Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
